ORIC

Oric Pharmaceuticals, Inc.

Tremor tracks 2 of its cancer trials.

Company-wide warning signs

These add points to every one of this company's trials.

None right now.

Trials

ORICORIC Pharmaceuticals
0Calm
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
Signing up patientsPhase 1/2350 patientsMain results: Jun 2027
ORICORIC Pharmaceuticals
0Calm
A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
Signing up patientsPhase 3600 patientsMain results: Mar 2028

Key executives leaving

From the last 12 months of the company's SEC reports.

None found.

Insider trades (last 6 months)

“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.

10 sales (0 not pre-planned) · 0 purchases

Piscitelli DominicChief Financial Officer · Oct 20, 2026Sold 14,000 sharesabout $189 thousand · pre-planned
Heyman Richard A.Board member · Oct 1, 2026Sold 3,500 sharesabout $45 thousand · pre-planned
Heyman Richard A.Board member · Oct 1, 2026Sold 3,200 sharesabout $41 thousand · pre-planned
Piscitelli DominicChief Financial Officer · Sep 28, 2026Sold 13,400 sharesabout $181 thousand · pre-planned
Piscitelli DominicChief Financial Officer · Sep 24, 2026Sold 100 sharesabout $1 thousand · pre-planned
Piscitelli DominicChief Financial Officer · Sep 24, 2026

Recent SEC filings

Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.

Money left

Coming soon: how many months of cash the company has, from its quarterly reports.